Physician profile
Utkarsh Acharya
NPI 1285860981
$7,566.06
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,132 · 2020: $198 · 2023: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $136.13 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 105 LLC | $2,784.24 | 2019 | |
| Seagen INC. | $2,656.70 | 2019-2020 | |
| Roche Molecular Systems, INC. | $1,600.00 | 2019 | |
| Astellas Pharma US INC | $194.00 | 2019-2020 | |
| Exelixis INC. | $99.99 | 2023 | |
| Amgen INC. | $95.00 | 2019 | |
| Pharmaessentia USA Corporation | $55.81 | 2023 | Besremi |
| Blueprint Medicines Corporation | $25.77 | 2023 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $21.28 | 2023 | |
| Incyte Corporation | $19.91 | 2023 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $13.36 | 2023 | Alunbrig |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Utkarsh Acharya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.